Anti-Human IL-23A (p19) (Tildrakizumab) – Fc Muted™

Anti-Human IL-23A (p19) (Tildrakizumab) – Fc Muted™

Product No.: I-2175

- -
- -
Product No.I-2175
Clone
MK-3222
Target
IL-23A (p19)
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
IL-23p19
Isotype
Human IgG1κ
Applications
FA

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Hamster
Expression Host
CHO Cells
FC Effector Activity
Muted
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
Purity
≥95% by SDS Page
≥95% monomer by analytical SEC
Formulation
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Liquid
Product Preparation
Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Additional Applications Reported In Literature ?
FA
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Tildrakizumab. MK-3222 (Tildrakizumab) targets the p19 subunit of IL- 23.
Background
IL-23 is a member of the IL-12 family of proinflammatory and immunoregulatory cytokines1 and plays a key role in the differentiation and proliferation of type 17 helper T cells (Th17)2. IL- 23 exists as a heterodimer composed of the IL-12p40 subunit and a novel p19 subunit that is shared with IL-393. IL-23 activities lead to the production of Th17-derived pro-inflammatory cytokines IL-17 and IL-221. Additionally, IL-23 possesses potent anti-tumor and anti-metastatic activity in mouse models of cancer, suggesting a potential role for IL-23 in therapeutic treatment of cancer4. IL-23 also contributes to chronic inflammation of immune-mediated diseases including psoriasis and psoriatic arthritis2.

Tildrakizumab is a humanized monoclonal antibody that inhibits IL-23 interaction with the IL-23 receptor by selectively binding the IL-23 p19 subunit5,6. Tildrakizumab has been approved for the treatment of plaque psoriasis.

Antigen Distribution
IL-23 is secreted by activated dendritic cells, macrophages, and monocytes.
Ligand/Receptor
IL12B, IL12RB1, IL23R
NCBI Gene Bank ID
UniProt.org
Research Area
Cancer
.
Immuno-Oncology
.
Immunology
.
Inflammatory Disease
.
Pro-Inflammatory Cytokines

References & Citations

1 Korn T, Oukka M, Kuchroo V, et al. Semin Immunol. 19(6):362-371. 2007.
2 Markham A. Drugs. 77(13):1487-1492. 2017.
3 Deodhar A, Gottlieb AB, Boehncke WH, et al. Lancet. 391(10136):2213-2224. 2018.
4 Wertheimer T, Zwicky P, Rindlisbacher L, et al. Nat Immunol. 25(3):512-524. 2024.
5 Markham A. Drugs. 78(8):845-849. 2018.
6 Khalilieh S, Hodsman P, Xu C, et al. Basic Clin Pharmacol Toxicol. 123(3):294-300. 2018.
7 Papp K, Thaçi D, Reich K, et al. Br J Dermatol. 173(4):930-939. 2015.
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.